{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:46:46Z","timestamp":1767066406007},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ejca.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T06:32:32Z","timestamp":1365402752000},"page":"2345-2355","source":"Crossref","is-referenced-by-count":9,"title":["A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer"],"prefix":"10.1016","volume":"49","author":[{"given":"El Mustapha","family":"Bahassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha M.","family":"Wise-Draper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen N.","family":"Darnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne I.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Stambrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.03.005_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2013.03.005_b0010","first-page":"3579","article-title":"Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are earlymarkers of carcinogenesis in head and neck cancer","volume":"53","author":"Grandis","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.03.005_b0015","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/jnci\/90.11.824","article-title":"Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival","volume":"90","author":"Grandis","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.03.005_b0020","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.03.005_b0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2013.03.005_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signalling","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ejca.2013.03.005_b0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2013.03.005_b0040","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.005_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermal growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2013.03.005_b0050","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1368-5031.2004.00369.x","article-title":"Cetuximab (Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours","volume":"58","author":"Ng","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejca.2013.03.005_b0055","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1073\/pnas.83.11.3825","article-title":"Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation","volume":"83","author":"Sunada","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2013.03.005_b0060","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2013.03.005_b0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.med.59.090506.202405","article-title":"EGFR tyrosine kinase inhibitors in lung cancer: an evolving story","volume":"59","author":"Sequist","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ejca.2013.03.005_b0070","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4161\/cbt.4.10.2102","article-title":"Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?","volume":"4","author":"Riely","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2013.03.005_b0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ccr.2004.05.028","article-title":"Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?","volume":"5","author":"Arteaga","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2013.03.005_b0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jnci\/dji238","article-title":"Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations","volume":"97","author":"Mukohara","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.03.005_b0085","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1158\/1535-7163.MCT-06-0506","article-title":"Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non-small cell lung cancers","volume":"6","author":"Doody","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2013.03.005_b0090","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdi356","article-title":"Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer","volume":"16","author":"Moroni","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.03.005_b0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.03.005_b0100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","article-title":"Evidence for a causal association between human papillomavirus and a subset of head and neck cancers","volume":"92","author":"Gillison","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.03.005_b0105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1082596","article-title":"Mutational analysis of the tyrosine kinome in colorectal cancers","volume":"300","author":"Bardelli","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejca.2013.03.005_b0110","first-page":"1648","article-title":"Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture","volume":"46","author":"Kamata","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2013.03.005_b0115","first-page":"3413","article-title":"Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region","volume":"21","author":"Mandic","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2013.03.005_b0120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1535-6108(04)00112-6","article-title":"Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression","volume":"5","author":"Chung","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2013.03.005_b0125","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/jnci\/djp177","article-title":"How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question","volume":"101","author":"Fojo","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.03.005_b0130","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/JCO.2009.25.2890","article-title":"Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane\/carboplatin in advanced non-small-cell lung cancer","volume":"28","author":"Khambata-Ford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.005_b0135","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.03.005_b0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2013.03.005_b0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1096\/fj.11-191064","article-title":"Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation","volume":"26","author":"Wang","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.ejca.2013.03.005_b0150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1349-7006.2012.02225.x","article-title":"Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy","volume":"103","author":"Hsieh","year":"2012","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.005_b0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/0019-509X.102865","article-title":"Risk factor profiles of head and neck cancer patients of Andhra Pradesh, India","volume":"49","author":"Addala","year":"2012","journal-title":"Indian J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913001913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913001913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T23:23:42Z","timestamp":1539732222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913001913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0959804913001913"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.03.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}